{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose", "query": { "intervention": "Intermediate dose" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 2623, "total_pages": 263, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T04:20:46.525Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00733798", "title": "A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Malignant Melanoma", "Metastatic Melanoma" ], "interventions": [ { "name": "131I-TM601", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TransMolecular", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2009-05-11", "last_synced_at": "2026-09-04T04:20:46.525Z", "location_count": 3, "location_summary": "Grand Rapids, Michigan • New York, New York • Dallas, Texas", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00733798" }, { "nct_id": "NCT05228184", "title": "Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Congenital Hypothyroidism" ], "interventions": [ { "name": "Tirosint®-SOL", "type": "DRUG" }, { "name": "Levothyroxine Sodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IBSA Institut Biochimique SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "9 Months", "sex": "ALL", "summary": "1 Day to 9 Months" }, "enrollment_count": 34, "start_date": "2022-01-21", "completion_date": "2025-03-27", "has_results": true, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-09-04T04:20:46.525Z", "location_count": 10, "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05228184" }, { "nct_id": "NCT01129258", "title": "Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Glucose Metabolism Disorders" ], "interventions": [ { "name": "PF-04991532", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 110, "start_date": "2010-06", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2011-03-09", "last_synced_at": "2026-09-04T04:20:46.525Z", "location_count": 4, "location_summary": "Chula Vista, California • Fountain Valley, California • Miami, Florida + 1 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01129258" }, { "nct_id": "NCT04603391", "title": "Cannabidiol and CES1 Interactions in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Drug Interaction" ], "interventions": [ { "name": "dl-Methylphenidate plus Cannabidiol", "type": "DRUG" }, { "name": "dl-Methylphenidate plus Cannabidiol Placebo solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "21 Years to 45 Years" }, "enrollment_count": 14, "start_date": "2021-02-25", "completion_date": "2021-12-31", "has_results": true, "last_update_posted_date": "2024-07-18", "last_synced_at": "2026-09-04T04:20:46.525Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04603391" }, { "nct_id": "NCT04879849", "title": "A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Triple Negative Breast Neoplasms", "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "TAK-676", "type": "DRUG" }, { "name": "Image-guided radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2021-09-09", "completion_date": "2024-04-30", "has_results": true, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-09-04T04:20:46.525Z", "location_count": 5, "location_summary": "Duarte, California • Chicago, Illinois • New York, New York + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04879849" }, { "nct_id": "NCT04047849", "title": "Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rupture of Membranes; Delayed Delivery (Following Spontaneous Rupture)", "Rupture of Membranes; Premature", "Rupture of Membranes; Premature, Affecting Fetus", "Preterm Birth", "Preterm PROM (Pregnancy)", "Preterm Labor" ], "interventions": [ { "name": "Antibiotics, oral Azithromycin and oral Amoxicillin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Woman's", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 34, "start_date": "2019-08-28", "completion_date": "2021-07-01", "has_results": false, "last_update_posted_date": "2021-01-11", "last_synced_at": "2026-09-04T04:20:46.525Z", "location_count": 1, "location_summary": "Baton Rouge, Louisiana", "locations": [ { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04047849" }, { "nct_id": "NCT04670926", "title": "Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Kidney Transplant Rejection", "Immunosuppression" ], "interventions": [ { "name": "TruGraf", "type": "DIAGNOSTIC_TEST" }, { "name": "Standard of Care", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "Transplant Genomics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2021-06-03", "completion_date": "2023-09-30", "has_results": false, "last_update_posted_date": "2021-08-27", "last_synced_at": "2026-09-04T04:20:46.525Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04670926" }, { "nct_id": "NCT01192815", "title": "Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "gene expression analysis", "type": "OTHER" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "biopsy", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "enzyme-linked immunosorbent assay", "type": "OTHER" }, { "name": "polymorphism analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 2, "start_date": "2011-01", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2020-05-12", "last_synced_at": "2026-09-04T04:20:46.525Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01192815" }, { "nct_id": "NCT05316155", "title": "Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Muscle Invasive Bladder Neoplasms" ], "interventions": [ { "name": "Erdafitinib Intravesical Delivery System", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2022-04-11", "completion_date": "2029-07-24", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-04T04:20:46.525Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Largo", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05316155" }, { "nct_id": "NCT04166058", "title": "Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Irritable Bowel Syndrome With Constipation", "Functional Constipation" ], "interventions": [ { "name": "Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers)", "type": "DRUG" }, { "name": "Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Years to 18 Years" }, "enrollment_count": 381, "start_date": "2019-11-19", "completion_date": "2025-06-05", "has_results": true, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-09-04T04:20:46.525Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Foley", "state": "Alabama" }, { "city": "Saraland", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04166058" } ] }